# Gossamer Bio (stock symbol: GOSS) Logo in transparent PNG and SVG formats

## Gossamer Bio Logo large

### Gossamer Bio Logo large Download PNG (153.04 KB)

![Gossamer Bio Logo large Download PNG (153.04 KB)](/img/orig/GOSS_BIG-aa035694.png)

### Gossamer Bio Logo large Download SVG (11.09 KB)

![Gossamer Bio Logo large Download SVG (11.09 KB)](/img/orig/GOSS_BIG-3b6d3923.svg)

## Gossamer Bio Logo icon format

### Gossamer Bio Logo icon format Download PNG (187.25 KB)

![Gossamer Bio Logo icon format Download PNG (187.25 KB)](/img/orig/GOSS-cb47dc7e.png)

### Gossamer Bio Logo icon format Download SVG (5.64 KB)

![Gossamer Bio Logo icon format Download SVG (5.64 KB)](/img/orig/GOSS-5e8ba19d.svg)

## Gossamer Bio Logo large for dark backgrounds

### Gossamer Bio Logo large for dark backgrounds Download PNG (153.1 KB)

![Gossamer Bio Logo large for dark backgrounds Download PNG (153.1 KB)](/img/orig/GOSS_BIG.D-1b58484c.png)

### Gossamer Bio Logo large for dark backgrounds Download SVG (10.76 KB)

![Gossamer Bio Logo large for dark backgrounds Download SVG (10.76 KB)](/img/orig/GOSS_BIG.D-f7ca562c.svg)

## About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

1. Website domain: gossamerbio.com
2. Employees: 185
3. Marketcap: $0.12 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
